Number of responders · IBD patients
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Pain frequency IBD (measured in days of pain on the IBS‐SSS questionnaire) · people with inflammatory bowel disease
1 finding from 1 review
Pain frequency or change in pain frequency · people with inflammatory bowel disease
1 finding from 1 review
Pain frequency CD (measured in days of pain on the IBS‐SSS questionnaire) · people with inflammatory bowel disease
1 finding from 1 review
Pain frequency or change in pain frequency · UC patients
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.4 [1.23, 1.6]
41 studies · 41 participants
Very low
OR 1.7 [1.38, 2.09]
17 studies · 17 participants
Low
OR 1.22 [1.03, 1.45]
24 studies · 24 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
Risk of postoperative infectious complications: 5‐ASA led to lower incisional infections and wound dehiscence within 30 days of surgery compared with control; GRADE not reported.
1 finding from 1 review
OR 0.53 [0.3, 0.95]
1 study · 1 participants
GRADE not reported
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: 5‐ASA changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.11 [0.97, 1.26]
31 studies · 31 participants
Very low
OR 1.29 [0.95, 1.76]
9 studies · 9 participants
Low
OR 1.07 [0.93, 1.24]
22 studies · 22 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐TNF agents changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.27 [1.09, 1.47]
54 studies · 54 participants
Very low
OR 1.6 [1.2, 2.13]
17 studies · 17 participants
Very low
OR 1.14 [0.96, 1.36]
37 studies · 37 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐TNF agents changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐TNF agents changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐TNF agents changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐integrin agents changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.11 [0.76, 1.62]
9 studies · 9 participants
Very low
OR 1.04 [0.79, 1.36]
2 studies · 2 participants
Low
OR 1.06 [0.54, 2.1]
7 studies · 7 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐integrin agents changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review